BioPharma Credit plc (BPCR) ORD USD0.01
Sell:$0.85
Buy:$0.85
0
Change:
No change
No change
Market closed |
Prices as at close on 24 December 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
- Add to watchlist
- Create an alert
- This stock can be held in a
Sell:$0.85
Buy:$0.85
Change:
No change
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Market closed |
Prices as at close on 24 December 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Sell:$0.85
Buy:$0.85
Change:
No change
No change
Market closed |
Prices as at close on 24 December 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Objective
To generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The Company will seek to achieve its investment objective predominantly through direct or indirect exposure to Debt Assets, which include Royalty Investments, Senior Secured Debt, Unsecured Debt and Credit Linked Notes.
| Security | Weight |
|---|---|
| Collegium | 18.98% |
| Lumira Dx | 11.34% |
| Insmed Inc | 11.00% |
| Coherus | 9.41% |
| BioCryst Pharmaceuticals Inc | 9.15% |
| Bms | 6.75% |
| OptiNose Inc | 5.38% |
| Evolus | 3.77% |
| Urogen | 3.77% |
| Immunogen Inc | 2.82% |
Top 10 sectors currently unavailable.
| Country | Weight |
|---|---|
| United States | 28.36% |
Fee Structure
Annual management fee is 1% of NAV. The performance fee is calculated as 10% of returns, subject to High Watermark and a 6% preferred return hurdle with 50% catch up.
Dividend Policy
The Company pays dividends in USD or GBP Sterling, if requested by a specific Shareholder, on a quarterly basis. The Company may, where the Directors consider it appropriate, use the reserve created by the cancellation of its Share premium account to pay dividends. The Company targets an annual dividend yield of 7% on the Ords (calculated by reference to the issue price at IPO), Dividends would be paid on March, June, September and December.
ASSET SPLIT
Trust Manager
Not currently available for this investment trust.
Manager Bio
Not currently available for this investment trust.
Board Of Directors
Harry HymanChairman, Duncan Budge, Rolf Soderstrom, Colin Bond, Stephanie Leouzon, Sapna Shah
Data policy - All information should be used for indicative purposes only. You should
independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete,
and accepts no responsibility for how it may be used.
Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.